These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 38025815)

  • 1. Erratum to cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: results from a prospective, observational study.
    Editorial Office
    Transl Lung Cancer Res; 2023 Oct; 12(10):2146-2147. PubMed ID: 38025815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: results from a prospective, observational study.
    Rounis K; Makrakis D; Tsigkas AP; Georgiou A; Galanakis N; Papadaki C; Monastirioti A; Vamvakas L; Kalbakis K; Vardakis N; Kontogianni M; Gioulbasanis I; Mavroudis D; Agelaki S
    Transl Lung Cancer Res; 2021 Aug; 10(8):3538-3549. PubMed ID: 34584855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erratum to evaluation of PD-L1 expression on circulating tumour cells in small cell lung cancer.
    Editorial Office
    Transl Lung Cancer Res; 2022 May; 11(5):950-952. PubMed ID: 35693287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC.
    Miyawaki T; Naito T; Kodama A; Nishioka N; Miyawaki E; Mamesaya N; Kawamura T; Kobayashi H; Omori S; Wakuda K; Ono A; Kenmotsu H; Murakami H; Notsu A; Mori K; Harada H; Endo M; Takahashi K; Takahashi T
    JTO Clin Res Rep; 2020 Jun; 1(2):100020. PubMed ID: 34589927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early Detection of Therapeutic Benefit from PD-1/PD-L1 Blockade in Advanced Lung Cancer by Monitoring Cachexia-Related Circulating Cytokines.
    Xu S; Miura K; Shukuya T; Harada S; Fujioka M; Winardi W; Shimamura S; Kurokawa K; Sumiyoshi I; Miyawaki T; Asao T; Mitsuishi Y; Tajima K; Takahashi F; Hayashi T; Harada N; Takahashi K
    Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic effect of cachexia in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
    Matsuo N; Azuma K; Murotani K; Murata D; Matama G; Kawahara A; Kojima T; Tokito T; Hoshino T
    Thorac Cancer; 2023 May; 14(15):1362-1367. PubMed ID: 37037511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correction: Effect of body tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors.
    Makrakis D; Rounis K; Tsigkas AP; Georgiou A; Galanakis N; Tsakonas G; Ekman S; Papadaki C; Monastirioti A; Kontogianni M; Gioulbasanis I; Mavroudis I; Agelaki S
    PLoS One; 2023; 18(11):e0294384. PubMed ID: 37943779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting the efficacy of first-line immunotherapy by combining cancer cachexia and tumor burden in advanced non-small cell lung cancer.
    Miyawaki T; Naito T; Doshita K; Kodama H; Mori M; Nishioka N; Iida Y; Miyawaki E; Mamesaya N; Kobayashi H; Omori S; Ko R; Wakuda K; Ono A; Kenmotsu H; Murakami H; Mori K; Harada H; Endo M; Takahashi K; Takahashi T
    Thorac Cancer; 2022 Jul; 13(14):2064-2074. PubMed ID: 35698259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.
    Ferrara R; Mezquita L; Texier M; Lahmar J; Audigier-Valette C; Tessonnier L; Mazieres J; Zalcman G; Brosseau S; Le Moulec S; Leroy L; Duchemann B; Lefebvre C; Veillon R; Westeel V; Koscielny S; Champiat S; Ferté C; Planchard D; Remon J; Boucher ME; Gazzah A; Adam J; Bria E; Tortora G; Soria JC; Besse B; Caramella C
    JAMA Oncol; 2018 Nov; 4(11):1543-1552. PubMed ID: 30193240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
    Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
    [No Abstract]   [Full Text] [Related]  

  • 11. Indirect comparison of sintilimab and other PD-L1 inhibitors for first-line treatment of non-squamous non-small-cell lung cancer.
    Zhang L; Qian Y; Li J; Cui C; Chen L; Qu S; Lu S
    Future Oncol; 2022 May; 18(15):1896-1905. PubMed ID: 35311347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erratum to combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer.
    Editorial Office
    Transl Lung Cancer Res; 2022 Mar; 11(3):504-505. PubMed ID: 35399569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous adverse events in lung cancer patients on the therapy based on PD-1/PD-L1 inhibitors: A prospective observational cohort study.
    Dang YC; Kong QT; Wang Z; Sang H
    Curr Probl Cancer; 2023 Feb; 47(1):100934. PubMed ID: 36580870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of weight loss on treatment with PD-1/PD-L1 inhibitors plus chemotherapy in advanced non-small-cell lung cancer.
    Miyawaki T; Naito T; Yabe M; Kodama H; Nishioka N; Miyawaki E; Mamesaya N; Kobayashi H; Omori S; Wakuda K; Ono A; Kenmotsu H; Murakami H; Mori K; Harada H; Takahashi K; Takahashi T
    Support Care Cancer; 2022 Feb; 30(2):1633-1641. PubMed ID: 34550461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of losing adipose tissue on outcomes from PD-1/PD-L1 inhibitor monotherapy in non-small cell lung cancer.
    Nishioka N; Naito T; Miyawaki T; Yabe M; Doshita K; Kodama H; Miyawaki E; Iida Y; Mamesaya N; Kobayashi H; Omori S; Ko R; Wakuda K; Ono A; Kenmotsu H; Murakami H; Takayama K; Takahashi T
    Thorac Cancer; 2022 May; 13(10):1496-1504. PubMed ID: 35420262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The benefit and risk of PD-1/PD-L1 inhibitors plus anti-angiogenic agents as second or later-line treatment for patients with advanced non-small-cell lung cancer: a systematic review and single-arm meta-analysis of prospective clinical trials.
    Chen S; Mo W; Jiang W; Zhou S; Gan H; Yu Q
    Front Immunol; 2023; 14():1218258. PubMed ID: 37614237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The influence of cachexia on the immunotherapy efficacy of Sintilimab for non-small cell lung cancer].
    Li XQ; Zhao ZL; Hou ML; Cui YX; Han SY; Fu FF
    Zhonghua Zhong Liu Za Zhi; 2021 Dec; 43(12):1292-1297. PubMed ID: 34915639
    [No Abstract]   [Full Text] [Related]  

  • 18. Real-world study of PD-L1 testing patterns and treatment distribution in patients with metastatic non-small-cell lung cancer in Israel.
    Moser SS; Apter L; Arunachalam A; Burke T; Shalev V; Chodick G; Siegelmann-Danieli N
    Immunotherapy; 2021 Jul; 13(10):851-861. PubMed ID: 34034511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-1/PD-L1 inhibitors plus anti-angiogenic agents with or without chemotherapy versus PD-1/PD-L1 inhibitors plus chemotherapy as second or later-line treatment for patients with advanced non-small cell lung cancer: A real-world retrospective cohort study.
    Chen S; Wei H; Zhao W; Jiang W; Ning R; Zhou S; Tan L; Wang H; Su C; He J; Zeng A; Zhao Y; Yu Q
    Front Immunol; 2022; 13():1059995. PubMed ID: 36569915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 expression as a prognostic marker in patients treated with chemotherapy for metastatic non-small-cell lung cancer.
    Woodford R; Zhou D; Lord SJ; Marschner I; Cooper WA; Lewis CR; John T; Yang JC; Lee CK
    Future Oncol; 2022 May; 18(14):1793-1799. PubMed ID: 35156837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.